Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224471 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
A Phase 3 study of Herpes Simplex, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
- 13
- Study locations
NCT00224471 is a Phase 3 study of Herpes Simplex that has completed, run by GlaxoSmithKline. The registered enrollment target is 671 participants, below the 1,557-participant average among 4 other Herpes Simplex trials with a reported enrollment target (57% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT00224471, a Phase 3 study of Herpes Simplex, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
- 13
- Study locations
Study Summary
Evaluate, one month after the third dose, the lot-to-lot consistency of 3 different commercial scale production lots of the candidate vaccine in healthy HSV 1-/2- females aged 10-17 years, determined by ELISA. Absence in significant variation for both parameters among the tested lots was hypothesized.
Conditions Studied
Interventions
- BIOLOGICAL GSK208141 vaccine
Study Locations (13)
Utah
- GSK Investigational Site - Salt Lake City
- GSK Investigational Site - Salt Lake City
Arizona
- GSK Investigational Site - Mesa
California
- GSK Investigational Site - Fountain Valley
Colorado
- GSK Investigational Site - Golden
Ohio
- GSK Investigational Site - Cincinnati
South Carolina
- GSK Investigational Site - Charleston
Texas
- GSK Investigational Site - Galveston
Washington
- GSK Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224471
The ClinicalTrials.gov registry entry for NCT00224471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,557-participant average among 4 other Herpes Simplex trials with a reported enrollment target (57% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Simplex appearing as the primary indexed condition, and to 1 intervention - of which GSK208141 vaccine is the first listed.
NCT00224471 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Utah, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00224471 about?
NCT00224471 is a clinical study titled "Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine". Evaluate, one month after the third dose, the lot-to-lot consistency of 3 different commercial scale production lots of the candidate vaccine in healthy HSV 1-/2- females aged 10-17 years, determined by ELISA. Absence in significant variation for both parameters among the tested lots was hypothesize...
What is the current status of trial NCT00224471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2003-12. Estimated completion is 2006-01.
What conditions does trial NCT00224471 study?
This clinical trial studies the following conditions: Herpes Simplex.
What interventions are being tested in trial NCT00224471?
The interventions under investigation include: GSK208141 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00224471?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224471 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Simplex
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
COMPLETED · Phase 3
-
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
COMPLETED · Phase 3
-
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
COMPLETED · Phase 3
-
Structure of the Herpes Simplex Virus Receptor
COMPLETED
-
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.